Menu
/REGISTER
Montecito
Nixon Peabody
Pac Premier
Loading...
You are here:  Home  >  'Bradway'
Latest

Amgen collaborating with Adaptive to create COVID-19 medicine

By   /  Thursday, April 2nd, 2020  /  Biotech, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Amgen collaborating with Adaptive to create COVID-19 medicine

Thousand Oaks-based biotech giant Amgen announced April 2 that it is collaborating with Adaptive Biotechnologies to discover and develop antibodies that can be used to prevent or treat COVID-19. Amgen shares gained 4 percent to $205.88 as of 10:25 a.m and Adaptive’s stock was up 0.8 percent to $27.72. Year-to-date, Amgen’s stock is down 14 Read More →

Read More →
Latest

Thousand Oaks biotech Amgen ponders acquisitions

By   /  Friday, February 7th, 2020  /  Biotech, Earnings, East Ventura County, Top Stories, Top Story, Tri-County Public Companies  /  Comments Off on Thousand Oaks biotech Amgen ponders acquisitions

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Dubroff: Boeing taps Amgen’s Bradway to navigate 737 MAX mess

By   /  Friday, April 12th, 2019  /  Biotech, Columns, Latest news, Tri-County Public Companies  /  Comments Off on Dubroff: Boeing taps Amgen’s Bradway to navigate 737 MAX mess

Henry Dubroff

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Judge rules for Amgen in patent dispute over Repatha competitor

By   /  Monday, February 25th, 2019  /  Biotech, East Ventura County, Latest news, Law, Technology  /  Comments Off on Judge rules for Amgen in patent dispute over Repatha competitor

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen Foundation donating $21 million to scholars program

By   /  Thursday, November 1st, 2018  /  Biotech, Central Coast Health Watch, East Ventura County, Education, Latest news, Tri-County Public Companies  /  Comments Off on Amgen Foundation donating $21 million to scholars program

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

New drugs boost profits at Amgen as two executives leave company

By   /  Friday, August 3rd, 2018  /  Central Coast Health Watch, Earnings, East Ventura County, left, Tri-County Public Companies  /  Comments Off on New drugs boost profits at Amgen as two executives leave company

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen revenues fall but profits increase

By   /  Wednesday, April 26th, 2017  /  Central Coast Health Watch, Earnings, East Ventura County, Latest news, Technology, Tri-County Public Companies  /  Comments Off on Amgen revenues fall but profits increase

Thousand Oaks-based biotech giant Amgen’s total revenues decreased by 1 percent to $5.5 billion during the first quarter of 2017, compared to the same period a year ago, according to an earnings report April 26. The drop was related to the plunge in sales of Enbrel, its rheumatoid arthritis drug. Sales decreased 15 percent due Read More →

Read More →